NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Youn H. Kim(Stanford University), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Jasmine Zain(City of Hope), Ahmad Halwani(University of Utah), Stefan K. Barta(University of Pennsylvania), Aaron C. Shaver(Vanderbilt University), Ryan A. Wilcox(University of Michigan), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Jeffrey A. Barnes(Harvard University), Amitkumar Mehta(University of Alabama at Birmingham), Carlos A. Torres‐Cabala(The University of Texas MD Anderson Cancer Center), Lubomir Sokol(Moffitt Cancer Center), Saurabh Rajguru(UW Health University Hospital), Weiyun Z. Ai(City College of San Francisco), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Gaurav Goyal(Glocal University), Andrei R. Shustov(Seattle Cancer Care Alliance), Stephen M. Ansell(Mayo Clinic), Kristopher Fisher(St. Jude Children's Research Hospital), Basem M. William(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Elise A. Olsen(Durham Technical Community College), Richard T. Hoppe(Stanford Medicine), Satish Shanbhag(Florida Cancer Specialists & Research Institute), Joan Guitart(Northwestern Memorial Hospital), Hema Sundar(National Comprehensive Cancer Network), Eric D. Jacobsen(Dana-Farber Cancer Institute), Matthew A. Lunning(University of Nebraska Medical Center), Sarah McCue Horwitz(New York University), Mark W. Clemens(The University of Texas MD Anderson Cancer Center), Aaron M. Goodman(University of California San Diego), Bradley M. Haverkos(University of Colorado Denver), Mary A. Dwyer(National Comprehensive Cancer Network), Barbara Pro(The University of Texas MD Anderson Cancer Center)
Cited by 121
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k